Visual abstract | Obinutuzumab in patients with LN: Post-hoc analyses of the phase II NOBILITY trial

Obinutuzumab is a recombinant, humanized anti-CD20 monoclonal antibody.¹ Treatment with obinutuzumab resulted in greater complete renal response at Week 52 (35% vs 23%; p = 0.115) and Week 104 (41% vs 23%; p = 0.026) in patients with lupus nephritis, versus placebo, meeting the primary endpoint of the phase II NOBILITY trial.^1-3 No safety signals were reported.¹

Below, we present a visual abstract summarizing a post-hoc analysis of the phase II NOBILITY trial on kidney outcomes with obinutuzumab, presented by Rovin et al.² at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), and by Rovin et al.³ published in Arthritis Rheumatol. We also include a post-hoc analysis by Vital et al.³ on B-cell recovery with obinutuzumab, presented at the ACR Convergence 2023.